Key takeaways
- A UCL-led review of more than 1 million women found no clear evidence that menopause hormone therapy (MHT) alters dementia risk.
- Findings support current guidelines that MHT should not be prescribed for dementia prevention.
- Evidence for both oestrogen-only and combined MHT showed very low certainty across most dementia and Alzheimer’s disease outcomes.
- Small signals of increased or decreased risk were observed in some analyses, but effects were trivial or inconsistent.
- Major evidence gaps remain for key subgroups, including women with early menopause, premature ovarian insufficiency, and non-oestrogen therapies.
Researchers from University College London (UCL) have found no evidence linking menopause hormone therapy (MHT) to increased or decreased dementia risk among post-menopausal women, publishing their findings in The Lancet Healthy Longevity.1
The review was the most comprehensive synthesis of evidence about this topic recorded to date, with over 1 million participants providing data. Investigators concluded the results reinforce current guidelines that hormone replacement therapy (HRT) should be guided by perceived risks and benefits, not for dementia prevention.
“Across the globe, dementia disproportionately affects women, even after accounting for women’s longer life spans, so there’s a pressing need to understand what might be driving that risk, and to identify ways to reduce women’s risk of dementia,” said Melissa Melville, a PhD student at UCL Psychology & Language Sciences.
Cognitive health assessments
The systematic review and meta-analysis were conducted to evaluate the impact of MHT on mild cognitive impairment or dementia in perimenopausal and postmenopausal women.2 Articles were obtained through systematic searches of the Embase, MEDLINE, PsycINFO, and Cochrane databases.
Studies published between January 1, 2000, and October 25, 2025, including perimenopausal or postmenopausal women, and reporting a quantitative association between MHT use and incident dementia or mild cognitive impairment were included. Women with premature ovarian insufficiency or early menopause were eligible for inclusion.
Data was extracted by 2 independent reviewers, with a third reviewer completing validation. These reviewers obtained data such as author details, year of publication, country of study, sample size, study design, participant demographics and baseline characteristics, intervention, comparator, outcomes, and measures of association.
Estrogen-only MHT and dementia risk
There were 15 articles included in the final analysis, with assessed outcomes including all-cause dementia, Alzheimer disease, and dementia or mild cognitive impairment. One of these studies found a potential increase in dementia risk from estrogen-only MHT in women aged at least 65 years, but this study had a low certainty of evidence.